Trial Profile
A prospective phase I and consecutive phase II, two arm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Dacarbazine; Etoricoxib; Pioglitazone; Trofosfamide
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2021 This trial has been completed in Germany, according to European Clinical Trials Database.
- 05 Jun 2012 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
- 05 Jun 2012 Planned end date 1 May 2016 added as reported by ClinicalTrials.gov.